Author:
Thompson Elizabeth D,Zahurak Marianna,Murphy Adrian,Cornish Toby,Cuka Nathan,Abdelfatah Eihab,Yang Stephen,Duncan Mark,Ahuja Nita,Taube Janis M,Anders Robert A,Kelly Ronan J
Reference44 articles.
1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
2. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014
3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014
4. Comprehensive molecular characterization of gastric adenocarcinoma;Cancer Genome Atlas Research Network;Nature,2014
5. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994;IARC Monogr Eval Carcinog Risks Hum,1994
Cited by
367 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献